Veriheal

DECEMBER 14, 2021

In accordance with this, a new study found that states with legal cannabis markets have been less likely to experience incidences of EVALI, suggesting that properly regulated vape pens are not the problem. An Analysis of Nationwide EVALI Data. ” The study also discovered impacts from other variances in policies across states.

Data 97

Data Vaping Legalization Consumption 97

The Cannigma

JUNE 30, 2021

On July 1st, 2021, new cannabis legalization are going into effect in Connecticut, New Mexico, and Virginia, just a couple days after a recreational cannabis legalization measure went into effect in South Dakota. Nearly half of all Americans now live in states where cannabis is legal for adult use. In Colorado, 78.7%

Chronic Pain 137

Chronic Pain Marijuana Conditions Patients 137

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. Food and Drug Administration (FDA) on December 1, 2021. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

The Cannigma

JANUARY 16, 2021

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. “That’s not really available in the cannabis industry,” he explained on the Cannabis Enigma podcast. Edited and mixed by Michael Schaeffer Omer-Man.

Data 100

Data Research and Development Patients Strains 100

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

NOVEMBER 2, 2021

While Michigan has undergone a price rout in 2021, with wholesale flower prices falling nearly $500 per pound, the state is virtually guaranteed to attract business from neighboring Ohio where medical cannabis is legal, but prices are significantly higher. or $288.10

Patients 52

Patients Retail Data Dispensary 52

Cannabis Law Report

JULY 16, 2021

PsyTech uses data-driven tools that allow physicians insight into patient well-being and clinical best practices. Empower Clinics reported total revenues of $2 million in the first quarter of 2021. The post Psychedellux July 16, 2021 appeared first on Green Market Report. also known as PsyTech Inc., PharmaDrug Inc.

Therapy 124

Therapy Data Patients 124

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? Also, a recent systematic review of healthcare professionals’ “cannabis knowledge” reported “there was a unanimous lack of self-perceived knowledge surrounding all aspects of medicinal cannabis” (2). million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Illinois News Joint

JANUARY 5, 2023

The Illinois Department of Public Health (IDPH) today reported December 2022 medical cannabis sales totals. were the most medical cannabis sales since April 2022 ($31,774,180.50). was less than total sales from 2021 and 2020. This total is a decrease from 2021 yearly totals of $397,249,781.70 2021 totals: $397,249,781.70.

Dispensary 76

Dispensary Patients Retail Cultivation 76

Cannabis Law Report

JULY 21, 2021

Akerna (Nasdaq: KERN ), an enterprise software, leading compliance technology provider, and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®) today announced the release of its second annual mid-year review. You can access the report here. About Akerna.

Supply Chain 105

Supply Chain Seed-To-Sale Data Research and Development 105

Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

SpeedWeed

JUNE 2, 2021

Nearly seven months have passed since the Green Wave of the 2020 election jumpstarted legalization of cannabis in multiple states across the United States, and with legalization comes market growth. . Cannabis Sales Growth. According to the data in the 2021 Annual Marijuana Business Factbook , U.S. billion in 2021.

Data 40

Data Media Business Cannabis 40

Cannabis Law Report

JULY 12, 2021

July 5, 2021 – July 9, 2021. CSE: MSET) revealed additional preclinical data showing strong efficacy and improved safety in a head-to-head comparison with psilocybin. PsyIndex Weekly Update. The PsyIndex moved marginally lower last week, giving up some gains from the prior week. Market Performance. Powered by.

Treatment 66

Treatment Decriminalization Pharmaceutical Data 66

Cannabis Law Report

JUNE 14, 2021

June 7, 2021 – June 11, 2021. OTCQB: SILO) announced a collaboration with UCSF to study psilocybin as an anti-inflammatory agent in Parkinson’s and bipolar patients. Crypto, Cannabis Backers Turn to Psychedelics with New UK IPO. Market Performance. Weekly Performance: $140.44 (15.04%). Powered by.

Research and Development 66

Research and Development Data Retail Programs 66

TheAnswerPage

NOVEMBER 19, 2021

According to a study published in the October 2021 edition of Cancer, what is the most common time for breast cancer patients to use cannabinoid-based products: pre-treatment, during treatment or after treatment? A Coala-T-Cannabis Survey Study of Breast Cancer Patients’ Use of Cannabis Before, During and After Treatment.

Treatment 52

Treatment Cannabinoids Data Patients 52

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JUNE 7, 2021

We increased the dosage to two doses of IGC-AD1 per day in Cohort 2, which was conducted from early February 2021 through mid-May 2021. The Phase 1 clinical trial on Alzheimer’s patients is currently anticipated to conclude during the July through September 2021 timeframe.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Illinois News Joint

AUGUST 4, 2023

Headset , a data platform for the cannabis economy, recently released a report that examined the Illinois cannabis market. According to Headset, “This report analyzes detailed data on thousands of products in the Illinois market to determine how it compares to other states. compared to 17.3% nationally.” on June 1, 2023.

Extraction 80

Extraction Data Edibles Cannabis 80

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. Both meetings are being held virtually.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

NOVEMBER 2, 2021

NORML is pleased to announce that its newly updated and revised publication, Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature, 2000 — 2021 , is now available for download on the Kindle app. Proceeds from the purchase of the new book directly fund NORML’s cannabis advocacy efforts.

Safety 52

Safety Patients Chronic Pain Advocacy 52

Veriheal

NOVEMBER 22, 2021

Have you ever wondered who spends more on cannabis: those who consume recreationally or for medicinal purposes? Headset , a leading cannabis data and market intelligence platform, recently conducted an audit of cannabis sales data around the United States—and the discoveries were interesting.

Recreational 89

Recreational Data Dispensary Cannabis 89

Cannabis Law Report

NOVEMBER 23, 2021

Tilray’s Leading European Footprint and Market Leadership in Germany Positions the Company to Seize Recreational Cannabis Opportunity. 22, 2021 (GLOBE NEWSWIRE) — Tilray, Inc. Last week, leaders in Germany’s incoming government coalition made substantial progress towards legalizing recreational cannabis in that market.

Research and Development 52

Research and Development Cultivation Pharmaceutical Packaging 52

Veriheal

NOVEMBER 24, 2021

For the first time ever, researchers will conduct a comprehensive state population health analysis to understand the impact of medical cannabis on consumers’ healthcare —and it’s all happening in Arkansas. A Deep Dive Into Cannabis Consumer Data. Vital patient records. To fund the study, a $1.3

Programs 84

Programs Research and Development Data Dispensary 84

Cannabis Law Report

JANUARY 6, 2022

This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy. patent awarded to COMPASS back in March 2021. Threat to Patient Access in Oregon. info@gl-lg.com ?

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

TheAnswerPage

APRIL 9, 2021

What is the most common qualifying condition reported by medical marijuana patients? Currently and historically, the most common qualifying condition reported by medical marijuana patients is chronic pain. Qualifying Conditions of medical cannabis license holders in the United States. Boehnke et al. Boehnke et al. See Answer.

Chronic Pain 69

Chronic Pain Conditions Data Patients 69

Veriheal

AUGUST 3, 2021

On Wednesday, June 30, Governor Tom Wolf (D) of Pennsylvania signed medical cannabis legislation amendments into effect. The newly signed legal framework will boost medical cannabis purchase limits, as well as prolong specific policies that were imposed on a temporary basis when the coronavirus (COVID-19) health crisis initially erupted.

Legislation 98

Legislation Patients Supply Chain Dispensary 98

Cannabis Law Report

JULY 23, 2021

SAN MARCOS — Parallel , one of the largest cannabis companies in the country, selected San Marcos as home to its new $25 million Texas headquarters for the medical cannabis company, goodblends. On April 19, 2021, construction began on three buildings, one retail and two industrial, totaling approximately 63,000 square feet.

Tincture 105

Tincture Patients Sleep Retail 105

Illinois News Joint

JANUARY 5, 2023

The Illinois Department of Financial and Professional Regulation (IDFPR) announced today the totals for adult-use cannabis sales in December and final total sales for the entire year. Illinois also sold the most cannabis items in one month since legalization at 3,446,978. and 20% from 2021 totals of $669,084,410.12.

Dispensary 76

Dispensary Recreational Cannabis Collective 76

Cannabis Law Report

OCTOBER 14, 2021

Canadian spending on medical cannabis fell to a five-year low in the first half of 2021, according to new data from Statistics Canada, as recreational marijuana reached record sales and more patients arranged to grow their own plants. In Canada, most medical cannabis is sold directly to patients via a licensed producer.

Data 52

Data Patients Recreational Cannabis 52

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE: Source: Data Bridge.

Research and Development 105

Research and Development Data Conditions Therapy 105

Veriheal

JANUARY 1, 2024

As debates heat up over recreational cannabis, all eyes turn to Ohio and its potential legalization. Once strictly prohibited nationwide, cannabis legislation has evolved remarkably across the U.S. For Ohio, sitting on the fence is becoming less tenable as neighboring states greenlight cannabis sales. in recent years.

Recreational 101

Recreational Supply Chain Legislation Cannabis 101

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. Based on this study and subject to FDA concurrence the cannabis-based investigational drug IGC-AD1 was generally safe and well-tolerated by the Alzheimer’s trial participants.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JUNE 1, 2021

TORONTO, June 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – RYAH Group, Inc. The 5-year study is expected to cover tens of thousands of patients suffering from chronic pain, which makes it one of the largest and most ambitious research projects to be conducted in the plant-based treatment arena. About RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

TheAnswerPage

AUGUST 3, 2021

Yes – Human experimental data suggests “THC has a dose-dependent effect on sleep—low doses appear to decrease sleep onset latency and increase slow-wave sleep and total sleep time, while high doses appear to cause sleep disturbances.” ” [link]. .” ” [link]. See the Answer.

Sleep 59

Sleep Data THC Cannabinoids 59

Cannabis Law Report

AUGUST 4, 2021

The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021. The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021.

Business 105

Business Research and Development Environment Food 105